The first to launch was the ACTT-1 trial, though it didn't have that name when it began at the University of Nebraska Medical ...

HC Wainwright reaffirmed their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a report issued ...

Of course, science around estrogen and menopause—a noteworthy time of estrogen loss—is largely lacking: Research suggests ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

AL002 misses Phase 2 goal in early Alzheimer's. Key Phase 3 data for latozinemab in 2025. Click here to read why ALEC is a ...

SNF-at-home programs are gaining traction as a viable solution to address the shortage of nursing home and rehabilitation ...

NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for ...

Arizona State Retirement System boosted its holdings in Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) by 34.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 17,033 ...

Nonsteroidal anti-inflammatory drug use for over 2 years was associated with a lower risk for dementia, especially ...

A parliamentary committee has expressed concern over posts of scientists in the Department of Health Research (DHR) lying vacant for an “unacceptably” long time and the continued exodus of trained and ...

Officers, 10% owners, and other insiders have shelled out more than $10 million on each of these four biotech stocks in the ...

Explore why Recursion Pharmaceuticals' AI-driven drug discovery faces challenges in revenue growth, governance, and investor ...